← Back to Search

Other

Vericiguat for Heart Failure and Cognitive Impairment (CONVERGE-HF Trial)

Phase 2
Waitlist Available
Led By Justin Ezekowitz, MBBCh, MSc
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Established chronic heart failure (≥ 6 months)
Be older than 18 years old
Must not have
Patients currently hospitalized
Patients who have contraindications for sGC stimulator and vericiguat therapy (i.e. use of long-acting nitrates, other soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5), pregnancy or breast-feeding)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 26 weeks
Awards & highlights
No Placebo-Only Group

Summary

"This trial is testing a new treatment for patients with chronic heart failure and mild-to-moderate memory problems."

Who is the study for?
This trial is for people who have had heart failure for at least 6 months and are also experiencing mild-to-moderate cognitive impairment. Specific eligibility criteria details are not provided.
What is being tested?
The CONVERGE-HF study is testing Vericiguat, a medication, to see if it can help patients with chronic heart failure and cognitive issues. It's a phase IIb trial conducted across four centers where participants are randomly chosen to receive the treatment.
What are the potential side effects?
Specific side effects of Vericiguat aren't listed here, but common ones may include dizziness, low blood pressure, or headaches based on its action in the body.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had chronic heart failure for at least 6 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently in the hospital.
Select...
I am not using long-acting nitrates, sGC stimulators, PDE-5 inhibitors, and I am not pregnant or breastfeeding.
Select...
I do not have severe kidney issues, incompatible heart devices, or uncontrolled heart rhythm problems.
Select...
I do not have uncontrolled thyroid issues, liver failure, recent heart procedures, severe dementia, or active cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~26 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 26 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in the lateral ventricular volumes.
Secondary study objectives
Blood Biomarkers (a)
Blood Biomarkers (b)
Clinical and patient-reported outcomes (6MWT)
+8 more

Side effects data

From 2019 Phase 3 trial • 5050 Patients • NCT02861534
15%
Hypotension
7%
Dizziness
7%
Anaemia
6%
Cardiac failure
5%
Nasopharyngitis
5%
Dyspnoea
5%
Diarrhoea
4%
Pneumonia
4%
Hyperkalaemia
3%
Acute kidney injury
2%
Chronic kidney disease
2%
Syncope
2%
Chronic obstructive pulmonary disease
1%
Ventricular tachycardia
1%
Gastroenteritis
1%
Sepsis
1%
Renal failure
1%
Cardiac failure congestive
1%
Cellulitis
1%
Atrial fibrillation
1%
Urinary tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vericiguat
Placebo

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: VericiguatExperimental Treatment1 Intervention
A starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. Uptitrated gradually every 2 weeks to 5 mg daily and then to the target dose of 10 mg daily.
Group II: Standard of CareActive Control1 Intervention
Conventional management of heart failure and mild-to-moderate cognitive impairment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vericiguat
2016
Completed Phase 3
~5050

Find a Location

Who is running the clinical trial?

Ottawa Heart Institute Research CorporationOTHER
194 Previous Clinical Trials
92,892 Total Patients Enrolled
22 Trials studying Heart Failure
11,280 Patients Enrolled for Heart Failure
Heart and Stroke Foundation of CanadaOTHER
129 Previous Clinical Trials
72,491 Total Patients Enrolled
7 Trials studying Heart Failure
1,285 Patients Enrolled for Heart Failure
University of AlbertaLead Sponsor
920 Previous Clinical Trials
431,644 Total Patients Enrolled
28 Trials studying Heart Failure
6,005 Patients Enrolled for Heart Failure
~80 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top